Canada’s Drug Agency | Drugs, Health Technologies and Systems.
Canada’s Drug Agency | Drugs, Health Technologies and Systems.

acalabrutinib

Details

Generic Name:
acalabrutinib
Project Status:
Pending
Therapeutic Area:
Mantle cell lymphoma (MCL)
Manufacturer:
AstraZeneca Canada Inc.
Call for patient/clinician input open:
Brand Name:
Calquence
Project Line:
Reimbursement Review
Project Number:
PC0413-000
Call for patient/clinician input closed:
Tumour Type:
Lymphoma
Biosimilar:
No
Manufacturer Requested Reimbursement Criteria1:
Acalabrutinib in combination with bendamustine and rituximab for the treatment of adult patients with previously untreated mantle cell lymphoma (MCL) who are ineligible for stem cell transplant (SCT).
Submission Type:
Initial
Fee Schedule:
Pending
Indications:
​Acalabrutinib in combination with bendamustine and rituximab for the treatment of adult patients with previously untreated mantle cell lymphoma (MCL).
Anticipated Date:
  1. The requested reimbursement criteria are provided by the applicant and do not necessarily reflect the views of Canada's Drug Agency. Reimbursement criteria from Canada's Drug Agency will be documented in the final recommendation, if applicable.
Last Updated : February 11, 2025